Welcome to Pipeline Review

Generex Biotechnology, and their wholly owned subsidiary Antigen Express, are developing promising new drugs to treat diabetes, as well as synthetic peptide vaccines targeting HER2/neu cancer and pandemic flu. The flagship product for Generex is Oral-lyn buccal insulin. Antigen Express' leading vaccine is the AE37 HER2/neu synthetic peptide vaccine to prevent breast cancer recurrence. I am not qualified to offer investment or medical advice, and make no claims that I am an expert in these areas. I am a layman and a shareholder in this company. The left side of Pipeline Review holds blogs regarding Generex and Antigen Express, while the right side offers items of due diligence mixed with my analysis which may be of interest to others seeking to learn about Generex's pipeline. If the left side only shows the latest blog, click on the word home to view them all.

Search This Blog

Monday, April 22, 2013

Two Abstracts Pertaining to the AE37 HER2/neu Vaccine Accepted as Poster Presentations at ASCO 2013

Two abstracts pertaining to Antigen Express' AE37 Her2/neu vaccine have been accepted for poster presentations at the 2013 American Society of Clinical Oncology ("ASCO") Annual Meeting. The annual ASCO meeting is being held in Chicago, Illinois from May 31 through June 4, 2013.

The abstract titles, with the name of the lead author, were revealed today with the launch of the meeting's iplanner. Here is the available information:

Abstract #3095

Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study.

Eleftheria A. Anastasopoulou

Abstract #3097

Risk factors for development of delayed urticarial reactions in the phase II trial of HER2 peptide vaccines plus GM-CSF versus GM-CSF alone in high-risk breast cancer patients to prevent recurrence.

Alfred F. Trappey, MD

The iplanner is available for review here.